Laser interstitial thermal therapy in older patients with drug‐resistant mesial temporal lobe epilepsy

Joanne Lau, Erica Von Stein, David Hartmann, Scheherazade Le, Jessica Falco‐Walter, Robert Fisher, Ashwin Ramayya, Vivek Buch, Niyatee Samudra
Epileptic Disorders · Wiley · 2026-11-16 · DOI: 10.1002/epd2.70468

Аннотация

Abstract Objective Laser interstitial thermal therapy (LITT) is a minimally invasive treatment for focal drug‐resistant epilepsy (DRE). This study sought to examine the efficacy of LITT for a cohort of older adults with mesial temporal lobe epilepsy (MTLE) and evaluate predictors of safety. Methods We examined 24 patients aged ≥50 years, with 10/24 (42%) ≥60 years. Primary outcomes were Engel classification and reduction from baseline seizure frequency. We additionally reviewed post‐ablation complications, hospital length of stay (LOS), neurocognitive and psychiatric worsening, and anti‐seizure medication (ASM) reduction. The Charlson Comorbidity Index (CCI) was calculated to assess its utility in prediction of postoperative complications. Results 22/24 (92%) had ≥50% reduction in seizure frequency, and 17/24 (71%) had ≥90% reduction at last follow‐up, with median follow‐up of 5.2 years (range, 1.5–10.4 years). Engel Class I outcome was achieved in 19/24 (79%) of patients by 6 months post‐ablation and maintained in 12/24 (50%) of patients by last follow‐up. Immediate postoperative complications were mostly transient, though worse cognitive symptoms were reported in 5/24 (21%), and worse mood was reported in 3/24 (13%) at 6 months post‐ablation. Higher CCI did not correlate with complications but was associated with prolonged LOS. ASM reduction occurred in half of patients. Significance In our cohort, LITT offered favorable seizure and safety outcomes in an older population with focal DRE. Perioperative risk assessments such as the CCI may be useful in older patient selection for LITT.

Читать у издателя →

Похожие статьи